Please check your internet connection and try again.
# Walethmade bromide
*Note: "Walethmade" is not a recognized pharmaceutical entity in clinical databases. Clinical evaluation suggests this may be a misspelling of **Aclidinium bromide**, an anticholinergic indicated for COPD. The following information applies to Aclidinium bromide.*
## Overview
Aclidinium bromide is a long-acting muscarinic antagonist (LAMA) that acts as a bronchodilator by inhibiting M3 receptors on airway smooth muscle. It is administered via an inhalation aerosol (dry powder inhaler).
## Primary Indications
Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
## Adult Dosing
400 mcg inhaled twice daily (every 12 hours). Do not exceed 400 mcg per dose.
## Pediatric Dosing
Not indicated for pediatric use. Safety and efficacy in patients under 18 years of age have not been established.
## Dose Adjustments
No dosage adjustment is required based on age, sex, or renal impairment. No specific data exist for hepatic impairment, though systemic exposure is low.
## Contraindications
Hypersensitivity to aclidinium bromide, atropine, or derivatives. Acute episodes of bronchospasm (not for rescue therapy).
## Adverse Effects
Common: Headache, nasopharyngitis, cough, sinusitis.
Serious: Paradoxical bronchospasm, anticholinergic effects (urinary retention, narrow-angle glaucoma exacerbation), worsening of cardiovascular status.
## Key Drug Interactions
Avoid concomitant use with other anticholinergic medications (e.g., tiotropium, ipratropium) as this may increase the risk of systemic anticholinergic adverse effects.
## Monitoring
Monitor for signs of paradoxical bronchospasm immediately after administration. Assess COPD symptom control and pulmonary function. In patients with history of urinary retention or narrow-angle glaucoma, monitor for worsening of symptoms.
## Clinical Pearls
* **Not a Rescue Medication:** This drug is not indicated for the relief of acute bronchospasm. A short-acting beta-agonist (e.g., albuterol) must be available for rescue use.
* **Administration:** Ensure the patient understands the use of the specific inhaler device (Genuair). Provide a puff-of-color or click-indicator confirmation check for device use.
* **Storage:** Keep in a dry place. Discard the inhaler if the indicator reaches zero or after the expiry period.
***
*Disclaimer: This information is for educational purposes and does not replace professional clinical judgment. Drug nomenclature and availability may vary by region. Always verify specific dosing, safety data, and local prescribing protocols via official package inserts or current institutional guidelines before administration.*
